Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › decitabine

decitabine

5 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of decitabine

55 trials tracked of decitabine: 6 in phase 3 or 4 and 4 with published results. The most-cited published study has 137 citations.

55Trials tracked
6Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 3 6 Phase 2 44 Phase 1 4 Other / NA 1
  1. Phase 3 Prospective Study of Patients With Thrombocytopenia Following HSCT Completed · 137 cited
  2. Phase 3 A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Completed · 10 cited
  3. Phase 3 A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia Completed · 8 cited
  4. Phase 3 Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Completed
  5. Phase 3 Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Completed
  6. Phase 3 Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML) Completed
Show 44 more trials
  1. Phase 2 Decitabine and Talazoparib in Untreated AML and R/R AML Completed
  2. Phase 2 Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease Completed
  3. Phase 2 Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS Completed
  4. Phase 2 Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome Completed
  5. Phase 2 An Efficacy and Safety Study of Decitabine in Participants With Myelodysplastic Syndrome (MDS) Completed
  6. Phase 2 A Trial to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML) Completed
  7. Phase 2 Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes Completed
  8. Phase 2 A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed
  9. Phase 2 Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed
  10. Phase 2 Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents Completed
  11. Phase 2 LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) Completed
  12. Phase 2 Trial of Decitabine as a Sensitizer to Carboplatin in Platinum Resistant Recurrent Ovarian Cancer Completed
  13. Phase 2 Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma Completed
  14. Phase 2 Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS) Completed
  15. Phase 2 Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia Completed
  16. Phase 2 Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant Completed
  17. Phase 2 Decitabine for Older or Unfit Patients With Acute Myeloid Leukemia (AML) Completed
  18. Phase 2 Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia Completed
  19. Phase 2 Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients Completed
  20. Phase 2 Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) Completed
  21. Phase 2 Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131 Completed
  22. Phase 2 Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk Completed
  23. Phase 2 Decitabine for High-Risk Sickle Cell Disease Completed
  24. Phase 2 Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS Completed
  25. Phase 2 Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed
  26. Phase 2 A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Completed
  27. Phase 2 Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) Completed
  28. Phase 2 A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS Completed
  29. Phase 2 Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS) Completed
  30. Phase 2 Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia Completed
  31. Phase 2 Study of Decitabine for Treatment of Older Patients With Acute Myeloid Leukemia (AML) Completed
  32. Phase 2 Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia Completed
  33. Phase 2 Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia Completed
  34. Phase 2 Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML) Completed
  35. Phase 2 Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes Completed
  36. Phase 2 Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS) Completed
  37. Phase 2 A Study of Decitabine Given to Adults With Advanced-Stage Myelodysplastic Syndromes Completed
  38. Phase 2 Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia Completed
  39. Phase 2 Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome Completed
  40. Phase 2 Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Completed
  41. Phase 2 Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia Completed
  42. Phase 2 Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML) Completed
  43. Phase 2 Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome Completed
  44. Phase 2 Trial of Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Completed

Showing the 50 most-cited and recently-updated of 55 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
AZA or LDAC combined with venetoclax likely improves mortality, remission, and quality of life
Oncology Meta-analysis
AZA or LDAC combined with venetoclax likely improves mortality, remission, and quality of life New combinations show promise for older adults with myeloid leukemia
This systematic review and meta-analysis of 47 studies evaluated treatments for older adults with AML ineligible for conventional chemothera…
Combining specific drugs like venetoclax with other treatments may improve survival and quality of life for older adults with acute myeloid …
Jun 12, 2026
Ven-Chi-Dec Regimen Induces Remission in Refractory Hodgkin Lymphoma
Allergy & Immunology Sys. Review
Ven-Chi-Dec Regimen Induces Remission in Refractory Hodgkin Lymphoma Venetoclax combo shows promise for relapsed Hodgkin lymphoma
A 26-year-old with relapsed/refractory classical Hodgkin lymphoma achieved complete metabolic remission after 6 cycles of venetoclax, chidam…
A 26-year-old man with relapsed Hodgkin lymphoma achieved complete remission after a novel three-drug regimen, with no significant side effe…
Frontiers May 15, 2026
Decitabine versus hydroxyurea in advanced chronic myelomonocytic leukemia shows survival differences linked to baseline counts
Oncology RCT
Decitabine versus hydroxyurea in advanced chronic myelomonocytic leukemia shows survival differences linked to baseline counts Keeping Blood Cell Counts Low in Leukemia Predicts Who Lives Longer
This randomized controlled trial (RCT) enrolled 120 patients with advanced proliferative chronic myelomonocytic leukemia (CMML) comparing de…
In chronic myelomonacytic leukemia, keeping abnormal blood cells low after treatment predicts who lives longer than bone marrow changes alon…
Apr 18, 2026
Meta-analysis finds HMA plus venetoclax yields 66% CR/CRi rate in younger, fit AML patients
Oncology Meta-analysis
Meta-analysis finds HMA plus venetoclax yields 66% CR/CRi rate in younger, fit AML patients Analysis finds promising results for leukemia treatment in younger patients
A meta-analysis of 429 younger, fit AML patients found HMA plus venetoclax yielded a 66% CR/CRi rate and 75% 1-year OS.
Younger acute myeloid leukemia patients treated with a specific drug combination achieved 75% one-year survival and 66% complete remission r…
Apr 5, 2026
Case report: CMML initially diagnosed as ITP in one patient, stabilized with decitabine
Hematology
Case report: CMML initially diagnosed as ITP in one patient, stabilized with decitabine A single case shows leukemia can initially look like a different blood disorder
A case report describes one patient initially diagnosed with immune thrombocytopenia (ITP) who was later found to have chronic myelomonocyti…
A single case shows leukemia can initially look like a different blood disorder, so doctors must watch for hidden mutations when standard tr…
Frontiers Apr 1, 2026